Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.

Tytuł:
Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.
Autorzy:
Oranje B; Center for Neuropsychiatric Schizophrenia Research (CNSR), Copenhagen University Hospital, Psychiatric Center Glostrup, Glostrup, Denmark. />Glenthøj BY
Źródło:
Schizophrenia bulletin [Schizophr Bull] 2013 May; Vol. 39 (3), pp. 684-91. Date of Electronic Publication: 2012 Jul 02.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2005- : Cary, NC : Oxford University Press
Original Publication: [Chevy Chase, Md., For sale by the Supt. of Docs., U. S. Govt. Print. Off. Washington]
MeSH Terms:
Schizophrenic Psychology*
Adrenergic alpha-2 Receptor Agonists/*pharmacology
Clonidine/*pharmacology
Cognition Disorders/*physiopathology
Schizophrenia/*physiopathology
Sensory Gating/*drug effects
Acoustic Stimulation ; Adrenergic alpha-2 Receptor Agonists/therapeutic use ; Adult ; Blinking/drug effects ; Clonidine/therapeutic use ; Cognition Disorders/drug therapy ; Cognition Disorders/psychology ; Cross-Over Studies ; Double-Blind Method ; Electromyography ; Habituation, Psychophysiologic/drug effects ; Humans ; Male ; Neural Inhibition/drug effects ; Reflex, Startle/drug effects ; Schizophrenia/drug therapy
References:
Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58. (PMID: 11549226)
Pharmacol Ther. 2007 Mar;113(3):523-36. (PMID: 17303246)
Arch Gen Psychiatry. 1996 May;53(5):448-55. (PMID: 8624188)
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):913-22. (PMID: 15363614)
Cortex. 2008 Oct;44(9):1206-14. (PMID: 18761134)
Biol Psychiatry. 2002 Nov 1;52(9):863-73. (PMID: 12399139)
Neuroimage. 2005 Jul 15;26(4):1052-8. (PMID: 15961045)
Psychiatry Res. 1989 Mar;27(3):297-311. (PMID: 2469097)
Acta Psychiatr Scand. 1982 Jan;65(1):35-45. (PMID: 6138923)
Arch Gen Psychiatry. 1990 Jun;47(6):589-93. (PMID: 2190539)
Psychiatry Res. 2004 Jul 15;127(3):195-205. (PMID: 15296819)
Int J Neuropsychopharmacol. 2007 Dec;10(6):787-95. (PMID: 17250777)
Psychopharmacology (Berl). 1996 Feb;123(4):353-60. (PMID: 8867875)
Neuropsychopharmacology. 2011 Apr;36(5):1003-14. (PMID: 21248721)
Psychopharmacology (Berl). 2004 Oct;175(4):399-406. (PMID: 15042278)
Behav Pharmacol. 1998 Nov;9(7):567-76. (PMID: 9862082)
Prog Neurobiol. 1999 Oct;59(2):107-28. (PMID: 10463792)
Neurosci Biobehav Rev. 1987 Winter;11(4):353-64. (PMID: 3325865)
Schizophr Bull. 1998;24(3):325-41. (PMID: 9718627)
Arch Gen Psychiatry. 1999 Mar;56(3):277-81. (PMID: 10078506)
Schizophr Res. 2008 Apr;101(1-3):185-94. (PMID: 18262774)
J Psychopharmacol. 1998;12(4):330-7. (PMID: 10065906)
Neuropsychopharmacology. 2001 Sep;25(3):402-9. (PMID: 11522468)
Schizophr Bull. 1987;13(2):261-76. (PMID: 3616518)
Neuropsychopharmacology. 2011 Jul;36(8):1656-67. (PMID: 21508929)
Science. 1978 Apr 28;200(4340):456-8. (PMID: 644310)
Psychopharmacology (Berl). 2006 Jun;186(2):246-54. (PMID: 16583235)
Schizophr Res. 2002 May 1;55(1-2):129-37. (PMID: 11955972)
Biol Psychiatry. 1999 Nov 1;46(9):1243-52. (PMID: 10560029)
J Clin Psychopharmacol. 1995 Oct;15(5):361-4. (PMID: 8830068)
J Psychiatry Neurosci. 2013 Jan;38(1):34-42. (PMID: 22687247)
Arch Gen Psychiatry. 2006 Dec;63(12):1325-35. (PMID: 17146007)
Int J Neuropsychopharmacol. 2010 Nov;13(10):1383-95. (PMID: 20633319)
Biol Psychiatry. 2009 Sep 15;66(6):614-20. (PMID: 19545856)
Biol Psychiatry. 2005 Jun 1;57(11):1377-84. (PMID: 15950011)
Schizophr Res. 1988 Nov-Dec;1(6):417-23. (PMID: 3154529)
J Psychopharmacol. 2000 Mar;14(1):40-5. (PMID: 10757252)
Psychiatry Res. 2003 Feb 15;122(2):99-113. (PMID: 12714174)
Neuropsychopharmacology. 2004 Jul;29(7):1282-93. (PMID: 15039766)
Substance Nomenclature:
0 (Adrenergic alpha-2 Receptor Agonists)
MN3L5RMN02 (Clonidine)
Entry Date(s):
Date Created: 20120704 Date Completed: 20131028 Latest Revision: 20211021
Update Code:
20240104
PubMed Central ID:
PMC3627754
DOI:
10.1093/schbul/sbs071
PMID:
22750632
Czasopismo naukowe
Background: Cognitive deficits form core features in schizophrenia. Several studies have shown improvements in prefrontal cognitive function by α 2 -agonists in schizophrenia. In the present study, it was investigated whether clonidine (an α 2 -adrenoceptor agonist) could normalize sensorimotor gating deficits in schizophrenia.
Methods: In a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine. Their results were compared with 20 age- and gender-matched healthy volunteers, who received no treatment.
Results: In the placebo treatment, patients showed deficient PPI and sensitization, yet normal habituation compared with the controls. Except the highest dose, all dosages of clonidine significantly increased percentage PPI in the patients compared with placebo, to such levels that it no longer differed significantly from the healthy controls. However, none of the dosages increased sensitization or influenced habituation.
Conclusions: This is the first study to show that even a single low dose of clonidine added to the medical treatment of patients with schizophrenia who are clinically stable on their antipsychotic medication not only significantly ameliorates their PPI deficits, but also normalizes them. The results have a potentially high clinical relevance for the medical treatment of schizophrenia.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies